Palbociclib

Drug Profile

Palbociclib

Alternative Names: Ibrance; PD-0332991; PD-332991; PD-991; PF-332991

Latest Information Update: 20 Jul 2017

Price : $50

At a glance

  • Originator Onyx Pharmaceuticals; Pfizer
  • Developer Assistance Publique Hopitaux de Paris; Canadian Cancer Trials Group; Dana-Farber Cancer Institute; Georgetown University; German Breast Group; GlaxoSmithKline; iOMEDICO AG; Karolinska Institute; Merck & Co; National Cancer Institute (USA); Netherlands Cancer Institute; Northwestern University; Pfizer; UNC Lineberger Comprehensive Cancer Center; University of California at San Francisco; Washington University School of Medicine
  • Class 2 ring heterocyclic compounds; Antineoplastics; Cyclopentanes; Ketones; Piperazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II/III Non-small cell lung cancer
  • Phase II Brain metastases; Colorectal cancer; Head and neck cancer; Prostate cancer; Urogenital cancer
  • Phase I/II Cancer; Malignant melanoma
  • Phase I Mantle-cell lymphoma; Pancreatic cancer; Solid tumours
  • No development reported Glioblastoma; Multiple myeloma

Most Recent Events

  • 14 Jul 2017 Pfizer plans a phase I drug-interaction trial in Healthy volunteers in USA (NCT03220191)
  • 30 Jun 2017 Phase-II clinical trials in Breast cancer (Early-stage disease, Newly diagnosed, Neoadjuvant therapy, Combination therapy) in USA (PO) (NCT02907918)
  • 30 May 2017 Pfizer initiates enrolment in the phase III PATINA trial for Breast cancer (Metastatic disease, Combination therapy, Recurrent, Inoperable/Unresectable) in USA (PO) (NCT02947685)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top